Accéder au contenu
Merck

[Clofibrate treatment of hyperlipoproteinemia].

Nihon rinsho. Japanese journal of clinical medicine (1994-12-01)
S Oikawa, H Midorikawa
RÉSUMÉ

Clofibrate has cholesterol- and triglyceride-lowering effect. They affect on the various points in the metabolic pathway of lipoproteins. They improve VLDL-synthesis in liver and increase the activity of LPL and hepatic TG lipase. As the results, HDL-cholesterol increases and LDL decreases. Therefore Clofibrate decreases not only plasma triglyceride but cholesterol levels. It has been reported that Clofibrate have a preventive effect on cardiovascular disease. So these agents are useful in the treatment for hyperlipidemic patients with or without atherosclerosis.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Clofibrate, liquid
Supelco
Clofibrate, analytical standard
Clofibrate, European Pharmacopoeia (EP) Reference Standard